Cipla
Arijit Das, PhD, currently serves as Senior Vice President and Global Head of API R&D at Cipla, overseeing the development of active pharmaceutical ingredients (API) across multiple locations, including Vikhroli, Pathalganga, and Bengaluru. With extensive experience in API development, including antiviral, steroid, and anticancer APIs, Das has held various leadership roles at Cipla, including Vice President and Global API R&D Head, and Senior Director and Head of Corporate API R&D. Prior to Cipla, Das played significant roles at Unichem Laboratories Limited, Takeda Pharmaceuticals, and the National Institutes of Health, contributing to medicinal chemistry projects and drug development. Das holds a PhD in Synthetic Organic Chemistry from the Indian Association for the Cultivation of Science and has completed the Cipla Leadership Ascent Program at Cornell University.
This person is not in the org chart
This person is not in any teams
Cipla
18 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.